215 related articles for article (PubMed ID: 18801061)
41.
Kumar D; Mehta A; Panigrahi MK; Nath S; Saikia KK
Turk J Haematol; 2018 Mar; 35(1):49-53. PubMed ID: 29129825
[TBL] [Abstract][Full Text] [Related]
42. Is the association of "cup-like" nuclei with mutation of the NPM1 gene in acute myeloid leukemia clinically useful?
Bennett JM; Pryor J; Laughlin TS; Rothberg PG; Burack WR
Am J Clin Pathol; 2010 Oct; 134(4):648-52. PubMed ID: 20855646
[TBL] [Abstract][Full Text] [Related]
43. Alport syndrome. Molecular genetic aspects.
Hertz JM
Dan Med Bull; 2009 Aug; 56(3):105-52. PubMed ID: 19728970
[TBL] [Abstract][Full Text] [Related]
44. Exhaustive analysis of the P53 gene coding sequence by denaturing gradient gel electrophoresis: application to the detection of point mutations in acute leukemias.
Pignon JM; Vinatier I; Fanen P; Jonveaux P; Tournilhac O; Imbert M; Rochant H; Goossens M
Hum Mutat; 1994; 3(2):126-32. PubMed ID: 8199593
[TBL] [Abstract][Full Text] [Related]
45. Gene expression with prognostic implications in cytogenetically normal acute myeloid leukemia.
Baldus CD; Bullinger L
Semin Oncol; 2008 Aug; 35(4):356-64. PubMed ID: 18692686
[TBL] [Abstract][Full Text] [Related]
46. Acute myeloid leukemia with mutated nucleophosmin (NPM1): any hope for a targeted therapy?
Falini B; Gionfriddo I; Cecchetti F; Ballanti S; Pettirossi V; Martelli MP
Blood Rev; 2011 Nov; 25(6):247-54. PubMed ID: 21724308
[TBL] [Abstract][Full Text] [Related]
47. Expression patterns of WT1 and PRAME in acute myeloid leukemia patients and their usefulness for monitoring minimal residual disease.
Qin Y; Zhu H; Jiang B; Li J; Lu X; Li L; Ruan G; Liu Y; Chen S; Huang X
Leuk Res; 2009 Mar; 33(3):384-90. PubMed ID: 18950857
[TBL] [Abstract][Full Text] [Related]
48. Contribution of multiparameter genetic analysis to the detection of genetic alterations in hematologic neoplasia. An evaluation of combining G-band analysis, spectral karyotyping, and multiplex reverse-transcription polymerase chain reaction (multiplex RT-PCR).
Preiss BS; Kerndrup GB; Pedersen RK; Hasle H; Pallisgaard N;
Cancer Genet Cytogenet; 2006 Feb; 165(1):1-8. PubMed ID: 16490591
[TBL] [Abstract][Full Text] [Related]
49. [Analysis of NPM1 gene mutations in acute myeloid leukemia].
Dai D; Zhang SJ; Qiao C; Sun XM; Qian SX; Xu W; Xu YL; Li JY
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2009 Apr; 17(2):294-7. PubMed ID: 19379554
[TBL] [Abstract][Full Text] [Related]
50. Assessment of Minimal Residual Disease in Standard-Risk AML.
Ivey A; Hills RK; Simpson MA; Jovanovic JV; Gilkes A; Grech A; Patel Y; Bhudia N; Farah H; Mason J; Wall K; Akiki S; Griffiths M; Solomon E; McCaughan F; Linch DC; Gale RE; Vyas P; Freeman SD; Russell N; Burnett AK; Grimwade D;
N Engl J Med; 2016 Feb; 374(5):422-33. PubMed ID: 26789727
[TBL] [Abstract][Full Text] [Related]
51. Prognostic impact of genetic characterization in the GIMEMA LAM99P multicenter study for newly diagnosed acute myeloid leukemia.
Lo-Coco F; Cuneo A; Pane F; Cilloni D; Diverio D; Mancini M; Testoni N; Bardi A; Izzo B; Bolli N; La Starza R; Fazi P; Iacobelli S; Piciocchi A; Vignetti M; Amadori S; Mandelli F; Pelicci PG; Mecucci C; Falini B; Saglio G;
Haematologica; 2008 Jul; 93(7):1017-24. PubMed ID: 18508799
[TBL] [Abstract][Full Text] [Related]
52. Altered nucleophosmin transport in acute myeloid leukaemia with mutated NPM1: molecular basis and clinical implications.
Falini B; Bolli N; Liso A; Martelli MP; Mannucci R; Pileri S; Nicoletti I
Leukemia; 2009 Oct; 23(10):1731-43. PubMed ID: 19516275
[TBL] [Abstract][Full Text] [Related]
53. [Combined application of multiplex reverse transcription-polymerase chain reaction and karyotype analysis to detection of clonal chromosomal aberrations in acute myeloid leukemia].
Huang L; Li CR; Zhang H; Sun LS; Liu WL; Zhou JF
Ai Zheng; 2007 Sep; 26(9):1029-33. PubMed ID: 17927867
[TBL] [Abstract][Full Text] [Related]
54. Capillary gel electrophoresis: a simple method for identification of mutations and polymorphisms in the CEBPA gene in patients with acute myeloid leukaemia.
Juhl-Christensen C; Bomberg M; Melsvik D; Hokland P; Nyvold CG
Eur J Haematol; 2008 Oct; 81(4):273-80. PubMed ID: 18616509
[TBL] [Abstract][Full Text] [Related]
55. Role of nucleophosmin in acute myeloid leukemia.
Meani N; Alcalay M
Expert Rev Anticancer Ther; 2009 Sep; 9(9):1283-94. PubMed ID: 19761432
[TBL] [Abstract][Full Text] [Related]
56. C-terminal nucleophosmin mutations are uncommon in chronic myeloid disorders.
Caudill JS; Sternberg AJ; Li CY; Tefferi A; Lasho TL; Steensma DP
Br J Haematol; 2006 Jun; 133(6):638-41. PubMed ID: 16704439
[TBL] [Abstract][Full Text] [Related]
57. DR negativity is a distinctive feature of M1/M2 AML cases with NPM1 mutation.
Syampurnawati M; Tatsumi E; Ardianto B; Takenokuchi M; Nakamachi Y; Kawano S; Kumagai S; Saigo K; Matsui T; Takahashi T; Nagai K; Gunadi ; Nishio H; Yabe H; Kondo S; Hayashi Y
Leuk Res; 2008 Jul; 32(7):1141-3. PubMed ID: 18180033
[TBL] [Abstract][Full Text] [Related]
58. A rapid, one step assay for simultaneous detection of FLT3/ITD and NPM1 mutations in AML with normal cytogenetics.
Huang Q; Chen W; Gaal KK; Slovak ML; Stein A; Weiss LM
Br J Haematol; 2008 Jul; 142(3):489-92. PubMed ID: 18477048
[No Abstract] [Full Text] [Related]
59. Detection of a novel CBFB/MYH11 variant fusion transcript (K-type) showing partial insertion of exon 6 of CBFB gene using two commercially available multiplex RT-PCR kits.
Park TS; Lee ST; Song J; Lee KA; Lee JH; Kim J; Lee HJ; Han JH; Kim JK; Cho SR; Choi JR
Cancer Genet Cytogenet; 2009 Mar; 189(2):87-92. PubMed ID: 19215788
[TBL] [Abstract][Full Text] [Related]
60. Absence of nucleophosmin 1 (NPM1) gene mutations in common solid cancers.
Jeong EG; Lee SH; Yoo NJ; Lee SH
APMIS; 2007 Apr; 115(4):341-6. PubMed ID: 17504301
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
